STAT News

STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more

The FDA rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis

作者 STAT News

1 分钟阅读
STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more
STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more

有活动行业的新闻要分享吗?

提交新闻稿或信息,触达数千名活动行业专业人士。

联系我们→

更多Health Tech相关内容

相关洞察